. | . |
Generic-Drug Companies To Produce Tamiflu Washington (UPI) Oct 20, 2005 Swiss drug company Roche Holdings, the sole manufacturer of Tamiflu, will meet with four generic-drug companies as early as next week in an attempt to boost production of the anti-viral medication, two senators said Thursday. Sens. Charles Schumer, D-N.Y., and Lindsey Graham, R-S.C., said they had received assurances from Roche that it would meet with Teva Pharmaceuticals, Barr Laboratories, Mylan Laboratories and Ranbaxy Pharmaceuticals in the coming days to determine how to boost production of Tamiflu, which is in high demand as a potential treatment to prevent infection by the avian-flu virus. Roche has agreed to issue manufacturing sub-licenses for the companies, "who demonstrate appropriate capabilities to manufacture Tamiflu in order to accelerate product supply," Schumer and Graham said in a news release issued prior to a meeting with reporters on Capitol Hill. The Food and Drug Administration still must approve all U.S. production standards, they said. The Department of Health and Human Services also will be involved. "The purpose here is not to break the patent on Tamiflu, but rather to meet an emergency need for quantities of this drug that Roche itself simply cannot do alone," Schumer said. Schumer had been pressuring the company to permit other manufacturers to produce Tamiflu and met with George Abercrombie, Roche's chief executive officer, before the news briefing, although Abercrombie did not attend. "I can't believe what we have been able to accomplish in the past 48 hours," Graham said. "It's breathtaking." So far, 40 countries worldwide have rushed to place Tamiflu orders with Roche because of rising public concern over the spread of the virus, which has been detected in Turkey, Greece and Romania and along the eastern edge of Africa. "We are all worried about a pandemic," Schumer said. "The experts say this pandemic is not an 'if,' but a 'when.'" He said the expanded supplies should begin reaching the market in about a month. H5N1, as this avian-flu virus strain is known, first began infecting humans in 1997 in Southeast Asia. Since then it has infected 120 people, most of whom have had close contact with birds. At present, there is no immunization available against the virus, and various strains can become resistant to anti-viral drugs such as Tamiflu over time. Roche holds the patent on the drug until 2016. -- Lizzie Wozobski is an intern for UPI. E-mail: [email protected] Related Links SpaceDaily Search SpaceDaily Subscribe To SpaceDaily Express Creating DNA Vaccine Could Help Save Lives, Slow Spread Of 'Bird Flu' London, UK (SPX) Oct 20, 2005 Researchers scrambling to combat a virulent form of bird flu that could mutate into a form easily spread among humans should consider developing vaccines based on DNA, according to British biochemical engineers. |
|
The content herein, unless otherwise known to be public domain, are Copyright 1995-2006 - SpaceDaily.AFP and UPI Wire Stories are copyright Agence France-Presse and United Press International. ESA PortalReports are copyright European Space Agency. All NASA sourced material is public domain. Additionalcopyrights may apply in whole or part to other bona fide parties. Advertising does not imply endorsement,agreement or approval of any opinions, statements or information provided by SpaceDaily on any Web page published or hosted by SpaceDaily. Privacy Statement |